PNT - POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

POINT Biopharma Global (NASDAQ:PNT) and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, also known as the Belgian Nuclear Research Center (“SCK CEN”), announce a technology license agreement for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added lutetium-177 (n.c.a. Lu-177) production program. POINT is licensing SCK CEN’s n.c.a. Lu-177 purification technology to both further increase the resiliency of its supply chain, as well as to lower cost of medical isotope, the most expensive raw material used in radiopharmaceutical production. “The scope and depth of our supply chain is now truly unique in the radiopharmaceutical industry and, when combined with our 80,000 ft² state-of-the-art manufacturing facility, make POINT one of the few firms globally capable of delivering radiopharmaceuticals for large cancer indications," said Dr. Joe McCann, CEO of POINT Biopharma. "We look forward to shipping our first clinical dose from our facility in the coming weeks,” Dr. McCann further added. Last month, PNT

For further details see:

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center